Washington Initiative 502 (2012)

Background

Washington had legalized medical cannabis in 1998 via Initiative 692, creating an affirmative defense for qualifying patients ^[1]. By the late 2000s a loosely regulated network of medical 'collective gardens' and dispensaries had grown up, particularly in Seattle, but the system existed in legal grey area and offered no protection for non-patients.

Multiple earlier attempts at broader reform had failed. A 2010 legalization bill (HB 2401) sponsored by Rep. Mary Lou Dickerson died in committee ^[2]. By 2011, a coalition began drafting what would become I-502, deliberately designed to attract mainstream voters rather than the existing activist base.

Drafting and Sponsors

The campaign committee, New Approach Washington, was led by a politically broad group including travel writer Rick Steves, former U.S. Attorney for the Western District of Washington John McKay, ACLU of Washington drug policy director Alison Holcomb (the initiative's principal drafter), Seattle City Attorney Pete Holmes, and former FBI Special Agent Charles Mandigo ^[3][4].

Holcomb is generally credited as the primary author. The drafting strategy was explicit: build a measure that suburban swing voters, parents, and law-enforcement-adjacent figures could endorse. That meant a state-run commercial system modeled in part on liquor regulation, a 21+ age limit, advertising restrictions, and — most controversially within the cannabis community — a per se DUI standard of 5 ng/mL active THC in blood ^[5].

The Campaign and Opposition

New Approach Washington raised roughly $6 million, with major contributions from Peter Lewis of Progressive Insurance and the Drug Policy Alliance ^[3]. The campaign ran television ads featuring mothers and former law enforcement, emphasizing regulation and tax revenue rather than cannabis itself.

Opposition came from two directions. Traditional opponents — some prosecutors, the Washington Association of Sheriffs and Police Chiefs (which took no formal position but had members publicly opposed), and anti-drug groups — argued legalization would increase youth use and impaired driving. More unusually, a faction of the medical cannabis community, organized as 'No on I-502' and including activist Steve Sarich, opposed the measure primarily over the 5 ng/mL DUI threshold, arguing it would criminalize sober patients with residual THC in their blood ^[6] Disputed.

The pharmacokinetic concern is real: chronic users can test above 5 ng/mL hours or days after last use without being acutely impaired ^[7] Strong evidence. Whether this has produced widespread wrongful DUI convictions in practice remains debated.

Passage and Federal Response

On November 6, 2012, I-502 passed with 55.7% of the vote. Colorado's Amendment 64 passed the same night. The two measures together made Washington and Colorado the first jurisdictions anywhere in the world to legalize, tax, and regulate adult-use cannabis through a commercial market (Uruguay's national legalization followed in 2013).

The immediate question was federal preemption: cannabis remained, and remains, a Schedule I substance under the federal Controlled Substances Act. On August 29, 2013, Deputy Attorney General James M. Cole issued what became known as the 'Cole Memo,' instructing federal prosecutors to deprioritize enforcement against state-legal cannabis activity that did not implicate eight specific federal priorities ^[8]. The memo provided the political cover for Washington and Colorado to build out their markets, though it was rescinded by Attorney General Jeff Sessions in January 2018 ^[9].

Implementation

The Washington State Liquor Control Board was given roughly a year to write rules. Personal possession of up to one ounce of flower became legal on December 6, 2012. Licensed retail sales began on July 8, 2014, with Cannabis City in Seattle among the first stores to open ^[10].

The rollout was tightly controlled. Unlike Colorado, Washington did not allow home cultivation for recreational users (and still does not, as of this writing). License caps, tracking requirements, and a three-tier producer/processor/retailer structure shaped the market. Tax structure was initially a 25% excise tax at three points of sale, later restructured in 2015 to a single 37% excise tax at retail ^[11].

The Medical Merger and Aftermath

I-502 did not address the existing medical system, which continued to operate in parallel. In 2015, the legislature passed SB 5052, the Cannabis Patient Protection Act, which folded most medical operations into the I-502 regulated structure, eliminated unregulated collective gardens, and created a voluntary patient registry ^[12]. Many longtime medical activists viewed this as the loss they had warned about in 2012.

Social-equity concerns also emerged. Early I-502 licensing did not include provisions for people with prior cannabis convictions or communities disproportionately harmed by prohibition; subsequent legislation (including HB 2870 in 2020) attempted to address this gap, with mixed results ^[13].

Popular mythology around I-502 has developed in two directions. Boosters sometimes describe it as a clean activist victory; in fact it passed over significant opposition from within the cannabis community. Critics sometimes describe it as having 'failed' because of the DUI threshold or medical merger; in fact it ended adult cannabis arrests for possession in Washington and generated over $500 million in annual cannabis excise tax revenue by the early 2020s ^[14]. Both framings flatten a genuinely complicated compromise.

Sources

How this page was made